The efficacy of curcuminoid in patients with overlapping gastroesophageal reflux disease and functional dyspepsia: A randomized controlled trial.

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20180530003

Enrollment

Registered

2018-05-30

Start date

2018-03-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

1. Gastroesophageal reflux disease (GERD) 2. functional dyspepsia curcuminoid gastroesophageal reflux gastric emptying gastric accommodation

Interventions

&#45

Anti&#45

OxÂ® in 1 capsule contains curcumin extract equivalent to curcuminoid 250 mg as the main substance and other compounds including colloidal silicon dioxide&#44

small amount of magnesium dioxide. The drug was registered by the Food and Drug Administration on August 3&#44

2013&#44

manufactured by Government Pharmaceutical Organization (GPO) This study was a randomized study. All subjects were randomly assigned to receive either curcumin or placebo by blocked randomizati

Placebo in 1 capsule contains 250 mg microcrystalline cellulose and other compounds including colloidal silicon dioxide&#44

small amount of magnesium dioxide. This study was a randomized study. All subjects were randomly assigned to receive either curcumin or placebo by blocked randomization method to divide patien

Experimental Drug,Experimental Drug

Curcuminoid,Placebo

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Diagnosis criteria for acid reflux disease are: 1. Age 18 - 70 years 2. Patients with burning sensation or tightness in the chest. And / or have food Stomach back up in the esophagus and / or sour or bitter. These symptoms interfere with the quality of life. Functional dyspepsia ROME IV criteria30 means patients with at least one of the following symptoms: - Bothersome postpradial fullness - Early satiety - Epigastric pain - Epigastriac burning pain Symptoms Continued at least 3 months and started onset for at least 6 months. 3. Upper gastrointestinal endoscopy for 6 months prior to study.

Exclusion criteria

Exclusion criteria: 1. Surgery in the abdomen except appendicitis, Maternity leave 2. Cancer of the gastrointestinal tract and liver 3. chronic inflammatory bowel disease inflammatory bowel disease 4. Cirrhosis, Chronic kidney disease 5. Depression 6. Upper gastrointestinal endoscopy results in 6 months before admission. The following abnormalities were observed: esophagus, gastric ulcer and duodenal ulcer. 7. Helicobacter pylori infection 8. Patients who take the drug with gastrointestinal effects and can not off the drug during research. 9. There are neurological diseases that can not be evaluated for pain. Uncontrolled psychiatric disorders and may want to adjust the drugs during study. 10. Have allergic curcumin. 11. Eat foods that component curcumin, regularly at least 3 days a week during the 1 month prior to study 12. Patients who can not sign the consent form for study participation.

Design outcomes

Primary

Measure	Time frame
Patient with GERD and functional dyspepsia responds to curcuminoid After 4 weeks of tintervention gastric accommodation and gastric emptying study,Relationship between treatment response and physiological changes of esophagus and stomach 4 weeks include lag time, gastric emptying half time, blood tests (TNFÎ±, IL1Î²)	—

Secondary

Measure	Time frame
Relationship between treatment response and physiological changes of gastroesophageal reflux disease After 4 weeks of intervention gastric accommodation and gastric emptying study,Changes in quality of life after taking curcuminoids and placebo. After 4 weeks of tinterventio Quality of Life Questionnaire Pre-Post, Weekly Symptoms Questionnaire, ,Side Effects of taking Curcuminoids and Placebo After 4 weeks of intervention gastric accommodation and gastric emptying study	—

Measure

Time frame

Relationship between treatment response and physiological changes of gastroesophageal reflux disease After 4 weeks of intervention gastric accommodation and gastric emptying study,Changes in quality of life after taking curcuminoids and placebo. After 4 weeks of tinterventio Quality of Life Questionnaire Pre-Post, Weekly Symptoms Questionnaire, ,Side Effects of taking Curcuminoids and Placebo After 4 weeks of intervention gastric accommodation and gastric emptying study

—

Countries

Thailand

Contacts

Public Contacttanisa Patcharatrakul,

Gastroenterology unit, Department of medicine, King Chulalongkorn Memorial

dr_tanisa@yahoo.com084-6653624

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026